Tuesday, 18 June 2013

EFIB 2013 – Get your Brochure now!

The European Forum for Industrial Biotechnology and the Biobased Economy 2013 (EFIB2013) takes place in Brussels from 30 September to 2 October at the Square conference facility. A full brochure for the event is now available – get your copy now!

With over 1,000 biotechnology professionals expected to attend, a growing exhibition hall with 50 exhibitors, over 14 hours of one-to-one networking available and a brand new Technology Showcase Theatre the EFIB has clearly continued to evolve for 2013.

"EFIB is the most important event on the calendar for the biobased economy," says Ian Hudson, President of DuPont EMEA and a member of the executive committee of Cefic and a board member at EuropaBio – joint organisers of the event with Smithers Rapra.

Diverse agenda
The new brochure shows the wide range of activities on offer at EFIB 2013 including:

  • Choose the conference agenda to suit your interests with 8 dedicated conference sessions focused on policy, finance, innovation and including a dedicated session on BRIDGE: the SusChem supported  proposal for a €3.8 billion Public Private Partnership (PPP) for the biobased industries
  • Be the first to witness the latest innovation and product development at the ‘new for 2013’ Technology Showcase in the Exhibition Hall
  • Take part in CEO Question Time and put your questions to the ‘movers and shakers’ in strategic positions to move the industry forward
  • Visit over 50 exhibitors and see for yourself first-hand what the European and wider industrial biotechnology industry has to offer
  • Take advantage of the one-to-one Partnering at EFIB2013 to make efficient use of your networking time, during over 14 hours of active partnering sessions

Get the brochure
Find out more about EFIB2013 in the brand new event brochure including the full programme, workshop agendas, exhibition floor plan, Technology Showcase Theatre agenda, one-to-one Partnering, prices, event highlights and travel information.

No comments:

Post a Comment

Please post your comment here. Please note that this newsblog is not moderated.